Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

3 Pages (Click to Jump) V   1 2 3 >

odi01
Posted on: Jul 19 2019, 02:25 PM


Group: Member
Posts: 572

https://au.finance.yahoo.com/news/why-costa...o2-z3aRAiUaYLc-
  Forum: By Share Code

odi01
Posted on: Jul 14 2019, 06:16 PM


Group: Member
Posts: 572

https://seekingalpha.com/article/4274537-eyes-biotech-m
  Forum: By Share Code

odi01
Posted on: Jul 13 2019, 05:37 PM


Group: Member
Posts: 572

https://www.greeleytribune.com/news/western...atment-options/
  Forum: By Share Code

odi01
Posted on: Jul 8 2019, 02:37 AM


Group: Member
Posts: 572

https://www.biotechdaily.com.au/
  Forum: By Share Code

odi01
Posted on: Jul 4 2019, 04:46 AM


Group: Member
Posts: 572

Very questionable, the FDA's decision

https://endpts.com/karyopharm-bags-an-upset...-of-objections/
  Forum: By Share Code

odi01
Posted on: Jul 1 2019, 03:29 PM


Group: Member
Posts: 572

https://au.finance.yahoo.com/news/10-best-s...o2-z3aRAiUaYLc-
  Forum: By Share Code

odi01
Posted on: Jul 1 2019, 03:07 PM


Group: Member
Posts: 572

https://smallcaps.com.au/avita-medical-publ...-recell-system/
  Forum: By Share Code

odi01
Posted on: Jul 1 2019, 02:10 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02119008
  Forum: By Share Code

odi01
Posted on: Jun 30 2019, 03:40 PM


Group: Member
Posts: 572

https://www.fool.com.au/2019/06/27/why-bubs...-value-in-2019/
  Forum: By Share Code

odi01
Posted on: Jun 25 2019, 02:31 PM


Group: Member
Posts: 572

https://kalkinemedia.com/2019/06/24/5-stock...ers-fy20-picks/

https://logmi.jp/business/articles/321338
  Forum: By Share Code

odi01
Posted on: Jun 20 2019, 11:50 PM


Group: Member
Posts: 572

https://gallery.mailchimp.com/73ce8c5905e2e...ks_for_FY20.pdf
  Forum: By Share Code

odi01
Posted on: Jun 17 2019, 07:25 PM


Group: Member
Posts: 572

https://thewest.com.au/business/markets/avi...-ng-b881232020z
  Forum: By Share Code

odi01
Posted on: Jun 16 2019, 05:12 PM


Group: Member
Posts: 572

http://www.aviseanalytics.com/scientific-b...-with-vitiligo/
  Forum: By Share Code

odi01
Posted on: Jun 15 2019, 02:35 PM


Group: Member
Posts: 572

https://seekingalpha.com/article/4270372-st...&app=1#alt1
  Forum: By Share Code

odi01
Posted on: Jun 15 2019, 01:41 AM


Group: Member
Posts: 572

https://freeshkreli.blogspot.com/2019/06/61...ml#comment-form
  Forum: By Share Code

odi01
Posted on: Jun 12 2019, 12:53 PM


Group: Member
Posts: 572

https://finance.yahoo.com/news/avita-medica...-023800060.html
  Forum: By Share Code

odi01
Posted on: Jun 11 2019, 04:40 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02113142
  Forum: By Share Code

odi01
Posted on: May 31 2019, 05:17 AM


Group: Member
Posts: 572

http://www.epp-deutschland.de/mediapool/21...htkranke_1_.pdf

http://www.epp-deutschland.de/mediapool/21...rankheit_1_.pdf
  Forum: By Share Code

odi01
Posted on: May 31 2019, 12:08 AM


Group: Member
Posts: 572

From Hotcopper

Adoption Rate Continues to Grow
Less than 6 months into its launch in the United States, the commercialisation of
ReCell continues to gather momentum at a faster rate than we had anticipated. There
are now 98 hospitals in the US either ordering or in evaluation of the Recell kits. This
represents approximately 70% of the specialist burns units in the country. By the end
of the year we expect the vast majority of these will have ordered product.
The recent American Burns Association Conference featured ten presentations
sponsored by Avita including a summary of the health economics for hospitals using
ReCell compared to the standard of care (SOC). The paper confirmed significant
savings to hospital operators in the treatment of burns patients. The savings are
estimated at between 14% to 17% per patient (across all burn sizes), with savings
increased for more severe burns requiring longer stays in hospital. This data is
compelling for value analysis committees and more than justifies the US$7,500 list
price for the ReCell kit. The major savings come from reduced volume of surgical
procedures per patient, reduced length of stay and reduced rehabilitation costs.
Finally, the company’s clinical program is advancing. A recent interim analysis of
Recell use in a paediatric population was awarded ‘Best Of The Best Abstract’ at the
American Burns Association Conference. In the study of 107 burn injuries, 98%
achieved closure within 4 weeks of treatment. This data is likely to be included in the
data dossier to extend the label claim for Recell to include children. The company will
begin enrolling patients in additional paediatric studies later this year.
Upgrade to Buy, Valuation raised to $0.68
The commercialisation of Recell is progressing well in the US and consequently we
have upgraded our unit sales forecast for FY21. We have also extended our
discounted cash flow model to 9 years. Valuation in raised to $$0.68 from $0.38 and
we upgrade our recommendation to Buy Speculative (from Hold)


Each account represents an individual hospital rather than a health care system or group.
The company had previously signalled its intention to target Burn Centres, hence it is not
unreasonable to assume most of the target accounts will specialise in the treatment of
burns. Collectively there are 98 hospitals across all three categories representing 70% of
the 134 specialist burns centres in the US.
The vast majority of accounts in the ‘prospecting’ stage are expected to proceed to Value
Analysis Committee (VAC).
We note a total of 45 burn accounts (including 106 burn surgeons) have been trained
relative to the 28 active accounts (i.e. ordering product). The difference between the
number of accounts trained vs ordering is most likely because 17 of the hospitals that have
received training are at Value Analysis Committee – i.e. normally surgeons have to be
trained in the use of the product and gain experience with its use prior to proposing a new
device to the VAC.
The key take out being that interest in the use of the ReCell system continues to grow.
These statistics are supportive of expectations for future sales growth. For surgeons, the
key driver of use is the patient outcome. Early results from first commercial use continue
to reflect the experience of users in the compassionate use program which operated in the
US prior to product approval.
Avita Medical sold approximately 224 recell kits for the March quarter to approximately 20
accounts. Prior to the official launch (Jan 2019) approximately 100 units has been sold in
the December quarter.
It seems reasonably clear that interest continues to swell. We do not expect there is any
significant stockpiling by hospital users, hence we are optimistic that the volume of sales in
the June quarter should grow by at least 50% (i.e. ~330 unit sales in the June 2019
quarter).
The company has not provided revenue guidance.



Find out how this one stock is combining the security and retail market.

InvestorsHub NewsWire
Promoted Yield Growth Announces Licensing Agreement for $1 Million Consideration for U.S. Rights to 56 White Label Formulations May 30, 2019 1:32 PM

Stocks to Watch as Oil & Gas Prices Stabilize • CXO • May 30, 2019 9:47 AM

Integrated Ventures Restarts Purchasing Mining Equipment From Bitmain Technologies As Bitcoin Pricing Approaches $9,000 • INTV • May 30, 2019 9:30 AM

ZVTK - Zevotek Announces Analyst Report Recommending Target $0.77 PPS Published By Goldman Small Cap Research • ZVTK • May 30, 2019 9:29
  Forum: By Share Code

odi01
Posted on: May 30 2019, 11:16 PM


Group: Member
Posts: 572

http://www.unimedizin-mainz.de/presse/pres...erkrankung.html
  Forum: By Share Code

odi01
Posted on: May 30 2019, 11:08 PM


Group: Member
Posts: 572

An estimated 400 patients have been diagnosed in Germany, and the number of unreported cases is very high," said Grabbe. "Here in Mainz, we expect about 50 patients per year."
  Forum: By Share Code

odi01
Posted on: May 30 2019, 11:03 PM


Group: Member
Posts: 572

New treatment centre in Mainz

In the Haut- und Poliklink of the Universitätsmedizin Mainz, the treatment of patients with EPP will begin in the foreseeable future. Here is the press release:



Department of Dermatology of the University Medical Center Mainz offers help for rare skin diseases

A drug approved on the German market since 2017 promises help for "erythropoietic protoporphyria" - application only possible at specialized centers

(Mainz, 28 May 2019, rdr) The Department of Dermatology at the University Medical Center Mainz is one of the few centers in Germany to offer a new treatment option for adult patients suffering from a rare hereditary disease, erythropoietic protoporphyria (EPP). EPP is associated with a painful sensitivity to light and sun and represents a great burden and restriction of quality of life for those affected.

"People who suffer from EPP experience severe pain when exposed to sunlight. Often no visible changes of the skin occur", describes Univ.-Prof. Dr. Stephan Grabbe, Director of the Mainz Skin Clinic. "On the one hand, this makes the diagnosis very difficult and, on the other hand, can lead to the fact that the patients' complaints are sometimes not taken seriously by the environment". All in all, the patients' level of suffering is high and their quality of life very limited, as they often have to avoid any sunlight, especially in the summer months.

EPP is caused by a genetic defect that causes the production of the red blood pigment to malfunction. In healthy people, this is produced in a final stage by the incorporation of iron into a chemical precursor - the protoporphyrin that gives the disease its name. If not enough iron can be incorporated, protoporphyrin is present in much larger quantities than usual. It then accumulates in the red blood cells and is responsible for the light intolerance. The reason for this is an interaction with visible light in the violet to blue range, which damages the tissue through various reactions and thus causes severe pain.

Until now, the only possible "remedy" was to consistently avoid sunlight and wear appropriate clothing with dense fabric, long sleeves and trouser legs, headgear, gloves and additionally an umbrella - i.e. textile sun protection. "Conventional UV sun creams do not protect, since the UV portion of the sunlight is not the problem", describes Stephan Grabbe. But now there is new hope for adult EPP patients - in the form of a medicine approved only under conditions. Its active ingredient, afamelanotide, stimulates the immune system and a protein that tans the skin; it thus stimulates pigmentation and the increased formation of pigment provides protection from within.

The special: The responsible authorities have only granted a limited approval for the drug because the safety of the drug could not yet be conclusively assessed due to the rarity of the disease and the relatively small number of patients associated with it. Treatment is only permitted to a few specialised centres, which collect further study data in the course of application. These centres now also include the university

Hautklinik Mainz - as one of now four centres in Germany and the only one in Southern Germany.
"EPP is still not curable, but for the first time we have a drug on hand with which we can significantly alleviate the symptoms of the disease," says Stephan Grabbe. "This is an enormous benefit for the patients. The active ingredient is administered in the form of a small capsule that is placed under the skin and dissolves there for 2 months. "This treatment must be carried out every 2 months, preferably throughout the whole year," describes Stephan Grabbe. "It is estimated that 400 patients are diagnosed in Germany and that the number of unreported cases is very high," says Grabbe. "Here in Mainz, we therefore expect about 50 patients per year."

"Since there is not yet a treatment place for every adult patient, the start of treatment in Mainz represents an enormous opportunity for many patients to live a life with a better quality of life," comments the board of directors of Selbsthilfe EPP e.V. on this news.



Contact:
University Professor Dr. Stephan Grabbe
Director of the Department of Dermatology and Polyclinic, Universitätsmedizin Mainz,
Tel. 06131 / 17 4412, Fax 06131 / 17 6629, E-Mail:

stephan.grabbe@unimedizin-mainz.de

Press contact:
Dr. Renée Dillinger-Reiter, Corporate Communications Department, University Medicine Mainz,
Tel. 06131 / 17 7428, Fax 06131 / 17 3496, E-Mail: pr@unimedizin-mainz.de

About the University Medicine of the Johannes Gutenberg-University Mainz
The university medicine of the Johannes Gutenberg-University Mainz is the only medical institution of the Supramaxima
  Forum: By Share Code

odi01
Posted on: May 29 2019, 02:37 PM


Group: Member
Posts: 572

Subject: Treatment option for adult patients with "Erythropoietic Protoporphyria - EPP" with the only available drug "Scenesse" / active substance "Afamelanotide" as well as difficult to access or inadequate care.

Dear Ladies and Gentlemen
As the first board member of Selbsthilfe EPP e. V. and accredited patient representative in the G-BA, I would like to ask you today for information in order to understand and clarify how a long-term treatment option is available to every adult patient with EPP.
On the facts: EPP is a genetic metabolic disease. Since the beginning of 2017, the only drug with the active ingredient "afamelanotide" has been approved on the German market. The requirements of the EMA/ December 2016/ are: Treatment / administration of the drug is only possible in certified centres / in a dermatological outpatient clinic / combined with a register study.
There are 3 centres in Germany: Charité Berlin/ ca.30 patients, Klinikum Chemnitz/ 20 patients and Uniklinik Düsseldorf/60 patients.
We know that in Düsseldorf alone 30 patients are on the waiting list.
The problem of the treatment on the part of the patients does not only consist in the high costs and time expenditure for the trips to the centres - travel costs and possibly necessary overnight stays are usually not taken over by the KK, working patients have to take a holiday / free, certificates of incapacity for work are hardly issued - but above all in the fact that there are not enough places for the treatment, so that patients are still waiting for the treatment. In Düsseldorf alone, there are 30 patients on a waiting list that cannot be processed in the foreseeable future due to a lack of personnel resources. Also our experience in the exchange with the therapists lets us assume that a durable treatment is not secured. At the beginning of 2019, for example, the University Hospital had not allocated any treatment appointments for its patients for the first time, as further treatment depended on the decision of the Executive Board. After our intervention, the treatment was confirmed for 2019 and appointments were made. "The treatment does not pay off" - we hear this again and again! Clinics say that costs for the medication are loss-making because the manufacturer does not give a "pharmacy discount". And ... and ... and ......
So far we know by contact with the PU that despite numerous inquiries no other clinics have decided for the treatment.
Our questions to you:
Who is responsible/who ensures that patients have access to treatment?
Why can hospitals refuse treatment?
The "pharmacist discount" situation in the clinics: does this also apply to orphan drugs?
What is the financing requirement for a treatment and what role does the so-called flat rate per case play?
The described facts are very complex, the so far experienced "hurdles and obstacles" in the treatment are very extensive in order to list them - which I like to do - but with this letter I first look for the conversation with you.
In a conversation with your predecessor, Mr. Laumann, as well as the employees Mr. Kronauer and Mrs. Wittchen, we were able to discuss the following issues with you.
Yours sincerely, Elke Hauke/ 1st Board Self-help EPP

http://www.epp-deutschland.de/mediapool/21...0513_Brief.docx
  Forum: By Share Code

odi01
Posted on: May 28 2019, 08:53 PM


Group: Member
Posts: 572

https://www.google.com/url?sa=t&source=...A28r3Zs-QQKUJlx
  Forum: By Share Code

odi01
Posted on: May 26 2019, 11:28 PM


Group: Member
Posts: 572

https://technobleak.com/regenerative-artifi...ming-worldwide/
  Forum: By Share Code

odi01
Posted on: May 22 2019, 01:15 PM


Group: Member
Posts: 572

https://finance.yahoo.com/news/does-clinuve...-222005039.html
  Forum: By Share Code

odi01
Posted on: May 21 2019, 11:40 PM


Group: Member
Posts: 572

https://hotcopper.com.au/documentdownload?i...eFxke92GA%3D%3D
  Forum: By Share Code

odi01
Posted on: May 21 2019, 02:54 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02107242
  Forum: By Share Code

odi01
Posted on: May 21 2019, 02:22 AM


Group: Member
Posts: 572

http://blackcranecap.com/avita-medical-par...n-regeneration/
  Forum: By Share Code

odi01
Posted on: May 20 2019, 05:06 AM


Group: Member
Posts: 572

http://life.eastmoney.com/a/201905171126582145.html
  Forum: By Share Code

odi01
Posted on: May 17 2019, 12:57 AM


Group: Member
Posts: 572

http://www.stockta.com/cgi-bin/analysis.pl...&mode=stock
  Forum: By Share Code

odi01
Posted on: May 17 2019, 12:50 AM


Group: Member
Posts: 572

https://www.fool.com.au/2019/05/16/why-the-...6-higher-today/
  Forum: By Share Code

odi01
Posted on: May 16 2019, 12:10 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02106162
  Forum: By Share Code

odi01
Posted on: May 14 2019, 12:29 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02105271
  Forum: By Share Code

odi01
Posted on: May 10 2019, 05:29 AM


Group: Member
Posts: 572

https://medtech.pharmaintelligence.informa....Pediatric-Trial
  Forum: By Share Code

odi01
Posted on: May 8 2019, 01:26 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02103690
  Forum: By Share Code

odi01
Posted on: May 7 2019, 01:19 PM


Group: Member
Posts: 572

https://rogermontgomery.com/where-to-for-avita-medical/
  Forum: By Share Code

odi01
Posted on: May 6 2019, 02:44 PM


Group: Member
Posts: 572

https://www.finnewsnetwork.com.au/archives/...work222784.html
  Forum: By Share Code

odi01
Posted on: May 4 2019, 06:55 PM


Group: Member
Posts: 572

Here's some pics of a severe chronic ulcer that was treated with ReCell:

https://i.imgur.com/XyQlcqP.png

The patient is an 84-year-old male that had an open skin wound for seven years. By week 7 of treatment, 85% of the wound was closed. By week 20, the wound closure had reached 96%.
  Forum: By Share Code

odi01
Posted on: May 4 2019, 03:46 PM


Group: Member
Posts: 572

https://www.youtube.com/watch?v=eLZQI3xXflA
  Forum: By Share Code

odi01
Posted on: May 2 2019, 07:59 PM


Group: Member
Posts: 572

https://www.lejdd.fr/Societe/Sciences/bient...atrices-3895704
  Forum: By Share Code

odi01
Posted on: May 2 2019, 03:10 PM


Group: Member
Posts: 572

https://www.avitamedical.com/uploads/pdf/AV...-2-May-2019.pdf
  Forum: By Share Code

odi01
Posted on: May 1 2019, 06:55 PM


Group: Member
Posts: 572

https://au.finance.yahoo.com/news/why-avita...-082729773.html

https://www.biospace.com/article/revolution...h-care-systems/
  Forum: By Share Code

odi01
Posted on: Apr 30 2019, 06:21 PM


Group: Member
Posts: 572

https://www.fool.com.au/2019/04/30/clinuvel...y-sales-growth/
  Forum: By Share Code

odi01
Posted on: Apr 29 2019, 05:45 AM


Group: Member
Posts: 572

Fiona Wood - IBM

https://www.ibm.com/blogs/industries/fiona-...linkId=65700663
  Forum: By Share Code

odi01
Posted on: Apr 26 2019, 01:25 PM


Group: Member
Posts: 572

https://www.harleystreetskinclinic.com/en/treatment/recell/
  Forum: By Share Code

odi01
Posted on: Apr 26 2019, 05:07 AM


Group: Member
Posts: 572

https://argera.com.au/services/problem-area...gmentation-loss
  Forum: By Share Code

odi01
Posted on: Apr 24 2019, 03:17 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02098450
  Forum: By Share Code

odi01
Posted on: Apr 23 2019, 11:17 PM


Group: Member
Posts: 572

https://youtu.be/o8c5Q1mEAhM
  Forum: By Share Code

odi01
Posted on: Apr 23 2019, 12:51 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02098096
  Forum: By Share Code

odi01
Posted on: Apr 18 2019, 03:10 PM


Group: Member
Posts: 572

https://www.dmgaz.org/make-better-torture-her/
  Forum: By Share Code

odi01
Posted on: Apr 18 2019, 03:02 PM


Group: Member
Posts: 572

https://walletinvestor.com/stock-forecast/c...tock-prediction
  Forum: By Share Code

odi01
Posted on: Apr 16 2019, 05:15 PM


Group: Member
Posts: 572

https://clinicaltrials.gov/ct2/results?cond...city=&dist=
  Forum: By Share Code

odi01
Posted on: Apr 13 2019, 01:20 PM


Group: Member
Posts: 572

Great statistics were presented at the meeting. A few listed here:
Best of the Best Abstract – Pediatric Burn Care

Dr. Carter presented data showing that 98% of mixed-depth/full-thickness burn Injuries in pediatric patients treated using Spray-On Skin Cells in combination with widely spaced meshed autografts were healed within four weeks of treatment. The presentation, titled
“Evaluation of a Pediatric Population Treated for Burn Injuries Using an Autologous Skin Cell Suspension: Interim Analysis,”
described the interim outcomes for 23 pediatric patients with a median age of 6.7 years old (ranging from 0.8 to 16.0) treated under FDA-IDE approved Compassionate Use and Continued Access programs. In patients with extensive burn injuries, lack of available donor skin is a major limitation achieving permanent closure; and the longer a wound remains open, the more susceptible a patient is to infection. In the U.S., one-third of burn injuries occur in children, and the availability of donor skin for traditional meshed autografts is even more limited in pediatric patients with extensive injuries. The use of the RECELL System, a donor skin sparing technology that enables rapid definitive closure of burn wounds, has the potential to improve patient outcomes.

In this study of pediatric patients which included those with life-threatening thermal burn injuries, Spray-On Skin Cells prepared using the RECELL System were applied in combination with widely meshed split-thickness autografts to achieve definitive closure using minimal donor skin. A total of 107 burn injuries were treated in the study, and 98% achieved definitive healing within four weeks of treatment. Importantly, for patients with greater than 50% total body surface area (TBSA) burns, treatment with the combination of Spray-On Skin Cells and widely meshed split-thickness autografts achieved the same high rate of healing at week four as patients with smaller burns (burns equal to or less than 50% TBSA) treated with the same combination. In addition, in the study the donor sites on all patients were treated with Spray-On Skin Cells, and 62.5% of the donor sites were healed within a week of treatment, and 100% were completely healed within two weeks of treatment.
“This interim analysis supports the use of the RECELL System as a viable option for treatment in these deeper burn injuries in pediatric patients,”
said Dr. Carter.
“In this vulnerable patient population, we observed excellent clinical outcomes with 98% of wounds healing within four weeks of treatment, and with the majority of burn sites having cosmetic outcomes rated as satisfactory or equivalent compared to uninjured skin. The early healing of donor sites contributed to a decrease between harvest times for patients with limited donor skin availability.”


https://www.bioportfolio.com/news/article/3..._medium=twitter

  Forum: By Share Code

odi01
Posted on: Apr 12 2019, 05:19 AM


Group: Member
Posts: 572

https://www.instagram.com/p/BwHv_cZnyYO/?ut...d=12ddsyics1vy8
  Forum: By Share Code

odi01
Posted on: Apr 11 2019, 06:03 AM


Group: Member
Posts: 572

Topical Cream??

https://twitter.com/ClinuvelNews/status/111...2569003008?s=17
  Forum: By Share Code

odi01
Posted on: Apr 10 2019, 03:43 PM


Group: Member
Posts: 572

https://www.fool.com.au/2019/04/10/why-the-...29-lower-today/
  Forum: By Share Code

odi01
Posted on: Apr 10 2019, 05:39 AM


Group: Member
Posts: 572

https://www.news-medical.net/news/20190408/...ELL-System.aspx
  Forum: By Share Code

odi01
Posted on: Apr 10 2019, 12:56 AM


Group: Member
Posts: 572

https://recellsystem.com/
  Forum: By Share Code

odi01
Posted on: Apr 9 2019, 08:14 PM


Group: Member
Posts: 572

https://www.fool.com.au/2019/04/09/why-the-...up-575-in-2019/
  Forum: By Share Code

odi01
Posted on: Apr 8 2019, 04:58 PM


Group: Member
Posts: 572

https://www.fool.com.au/2019/04/08/why-atom...d-higher-today/
  Forum: By Share Code

odi01
Posted on: Apr 8 2019, 12:49 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02094093



https://www.asx.com.au/asx/statistics/displ...;idsId=02094070
  Forum: By Share Code

odi01
Posted on: Apr 7 2019, 08:17 PM


Group: Member
Posts: 572

https://thefly.com/landingPageNews.php?id=2889148
  Forum: By Share Code

odi01
Posted on: Apr 5 2019, 03:29 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02093625
  Forum: By Share Code

odi01
Posted on: Apr 4 2019, 05:57 AM


Group: Member
Posts: 572

https://www.fool.com.au/2019/04/02/is-it-to...ing-asx-shares/
  Forum: By Share Code

odi01
Posted on: Apr 4 2019, 05:53 AM


Group: Member
Posts: 572

https://academic.oup.com/jbcr/search-result...;fl_SiteID=6140
  Forum: By Share Code

odi01
Posted on: Mar 31 2019, 01:59 AM


Group: Member
Posts: 572

http://ameriburn.org/education/annual-meeting/


https://avitamedical.com/uploads/pdf/AVITA-...-March-2019.pdf
  Forum: By Share Code

odi01
Posted on: Mar 30 2019, 11:51 PM


Group: Member
Posts: 572

MARCH 30, 2019 -

On 27 March, Rocco Falchetto was a guest speaker at the Trend Days Health Lucerne, one of the most important national platforms for the exchange of experience and the promotion of opinion-forming on trends and perspectives in the Swiss healthcare system. It was a unique opportunity to speak to an audience of key players and decision-makers in the healthcare system about the challenges in the field of rare diseases and in particular EPP! Watch the recording of his presentation on YouTube. The slides of the presentation can be found here:


https://www.change.org/p/ein-leben-ohne-son...amp;utm_term=cs
  Forum: By Share Code

odi01
Posted on: Mar 27 2019, 11:58 PM


Group: Member
Posts: 572

https://recellsystem.com
  Forum: By Share Code

odi01
Posted on: Mar 18 2019, 02:06 AM


Group: Member
Posts: 572

https://www.instagram.com/p/BvHRo3LDYRe/?ut...d=1vunw0n2jz7yp
  Forum: By Share Code

odi01
Posted on: Mar 16 2019, 05:12 PM


Group: Member
Posts: 572

https://backend.otcmarkets.com/otcapi/compa...t/35394/content
  Forum: By Share Code

odi01
Posted on: Mar 16 2019, 03:51 PM


Group: Member
Posts: 572

https://www.businessnews.com.au/article/Bus...ect-on-25-years
  Forum: By Share Code

odi01
Posted on: Mar 16 2019, 03:33 PM


Group: Member
Posts: 572

https://www.businessinsider.my/inventions-by-women-2017-8/

In the early 1990s, Dr. Fiona Wood revolutionized medical treatment for burn victims when she created spray-on skin.
  Forum: By Share Code

odi01
Posted on: Mar 14 2019, 05:14 PM


Group: Member
Posts: 572

https://www.businesswire.com/news/home/2019...m-Presentations
  Forum: By Share Code

odi01
Posted on: Mar 14 2019, 12:50 AM


Group: Member
Posts: 572

https://www.businesswire.com/news/home/2019...any-Health-Care
  Forum: By Share Code

odi01
Posted on: Mar 13 2019, 07:39 PM


Group: Member
Posts: 572

http://www.epp-deutschland.de/index.html

Last year, the portrait of Carina made us aware of the special situation of the patients with EPP. In all 3 centres in Germany-Berlin, Chemnitz and Düsseldorf- patients are still being treated, but: there are still not enough places available - so Jürgen B. has been waiting for a long time - still many patients have to travel long distances, bear the costs for it themselves, and most patients get only 4 implants, but experience shows: a permanent protection over the whole year is necessary to be sufficiently protected, in order not to be exposed to the pain again in the time without treatment and to fall into the old patterns of fear!!! Experiences of patients who receive 6 implants show that only permanent protection is an optimal protection.



With the health insurance companies many, but not all patients find support for this improvement in the treatment, and further there are also on the part of the centers among other things supply bottlenecks.

  Forum: By Share Code

odi01
Posted on: Mar 12 2019, 04:30 PM


Group: Member
Posts: 572

https://www.businesswire.com/news/home/2019...m-Presentations
  Forum: By Share Code

odi01
Posted on: Mar 8 2019, 11:27 PM


Group: Member
Posts: 572

https://www.thedailybeast.com/martin-shkrel...ind-bars-report
  Forum: By Share Code

odi01
Posted on: Mar 8 2019, 03:59 PM


Group: Member
Posts: 572

https://www.biospectrumasia.com/news/27/129...e-in-japan.html
  Forum: By Share Code

odi01
Posted on: Mar 6 2019, 03:14 AM


Group: Member
Posts: 572

https://www.businesswire.com/news/home/2019...SMOTEC-M3-Group
  Forum: By Share Code

odi01
Posted on: Mar 5 2019, 10:25 PM


Group: Member
Posts: 572

https://www.afr.com/business/rich-bosses-20...20190304-h1bz1a
  Forum: By Share Code

odi01
Posted on: Feb 23 2019, 04:38 PM


Group: Member
Posts: 572

http://www.mysmarttrader.com/top-picks.aspx
  Forum: By Share Code

odi01
Posted on: Feb 9 2019, 05:48 AM


Group: Member
Posts: 572

https://www.facebook.com/clinuvel/posts/10156586465821311
  Forum: By Share Code

odi01
Posted on: Feb 2 2019, 03:11 PM


Group: Member
Posts: 572

https://www.dagensmedisin.no/artikler/2019/...--tre-fikk-nei/

No to implant
Decision forum also rejected afamelanotide (Scenesse), which is a so-called orphan drug. The implant is used in the treatment of arythropoietic protoporphyria ( EPP), a rare and hereditary disease that can cause severe pain in skin areas that have been exposed to sunlight or strong daylight. There are no recommended treatment options today. The Norwegian Medicines Agency has considered that cost effectiveness is not documented for afamelanotide.

About 40 patients may be appropriate for treatment in Norway, but the Decision Forum says no.

- The drug has relatively little effect at a considerable cost. Therefore we say no, reason Slørdahl.
  Forum: By Share Code

odi01
Posted on: Jan 31 2019, 04:23 PM


Group: Member
Posts: 572

https://www.businesswire.com/news/home/2019...-Quarterly-Cash
  Forum: By Share Code

odi01
Posted on: Jan 25 2019, 05:09 PM


Group: Member
Posts: 572

https://investingnews.com/daily/life-scienc...x-best-50-list/
  Forum: By Share Code

odi01
Posted on: Jan 25 2019, 04:39 AM


Group: Member
Posts: 572

The Australian pharmaceutical company Clinuvel Pharmaceuticals specializes in the treatment of skin diseases, a growing market worldwide. The most promising product, Scenesse, is to be used to treat pigment disorders. The application for FDA approval in the USA for the treatment of extreme sensitivity to light (EPP) has just been accepted with a shortened procedure. The urgency note not only increases the chances of final approval for EPP, but also for the treatment of other diseases.

In the long term, we see opportunities in the expansion of the treatment spectrum. Smaller studies have also shown efficacy in white spot disease, which affects around 50 million people worldwide. The company operates with a margin of over 50 percent. The increase in sales and earnings after taxes, the low gearing ratio and the strong cash position also speak in favor of an investment. According to analysts, the intrinsic value of the share is 36 Australian dollars, which results in a price potential of over 60 percent.

https://www.finanzen.net/nachricht/aktien/e...uticals-7038721
  Forum: By Share Code

odi01
Posted on: Jan 22 2019, 08:03 PM


Group: Member
Posts: 572

https://www.equities.com/news/avita-medical...or-severe-burns
  Forum: By Share Code

odi01
Posted on: Jan 18 2019, 03:06 AM


Group: Member
Posts: 572

From minute 36

https://youtu.be/ZO5qESomqt4?list=PL0u8um2G...apO0QnTQEaDD1RY
  Forum: By Share Code

odi01
Posted on: Jan 9 2019, 06:00 AM


Group: Member
Posts: 572

https://finance.yahoo.com/news/avita-medica...-040500707.html
  Forum: By Share Code

odi01
Posted on: Jan 5 2019, 02:44 AM


Group: Member
Posts: 572

https://www.pm360online.com/pm360-presents-...018-innovators/
  Forum: By Share Code

odi01
Posted on: Jan 5 2019, 02:42 AM


Group: Member
Posts: 572

https://www.pm360online.com/pm360-2018-inno...-avita-medical/
  Forum: By Share Code

odi01
Posted on: Dec 23 2018, 11:11 PM


Group: Member
Posts: 572

https://www.change.org/p/licht-f%C3%BCr-all...amp;utm_term=cs

23DEC. 2018 —

Tonight a touching comment reached me: Jenny is 12 years old, has erythropoietic protoporphyria (EPP) - and is bullied for it. As if it wasn't bad enough to have EPP already...

Jenni doesn't know anyone with the disease and fortunately has contacted me with her concerns about my YouTube channel. Because together it's easier to deal with all the challenges.

Gabi, also an EPP patient, now had a wonderful idea to show Jenni that she has support:

"Hello Jenni...you are not alone with this disease...there are some of us...but we have good times too. We now have the winter �das is such a beautiful time and you have people who understand you...e.g. the shadow jumpers...let's go people...tell Jenni that life can also be beautiful".

Please support Gabi's call, and tell Jenni via YouTube or change.org that life with EPP is definitely worth living and beautiful!

Original Post from YouTube (Jenny)
I still have EPP as a child and therefore I am bullied at the age of 7. Now I am almost 12 years old and I am thinking if I will survive until my birthday.
  Forum: By Share Code

odi01
Posted on: Dec 23 2018, 06:25 PM


Group: Member
Posts: 572

https://www.zdf.de/gesellschaft/sonntags/fa...tml#xtor=CS5-95

5,12 min
  Forum: By Share Code

odi01
Posted on: Dec 20 2018, 11:42 PM


Group: Member
Posts: 572

http://www.porphyria.ch/download/CorrieredelTicino.pdf
  Forum: By Share Code

odi01
Posted on: Dec 14 2018, 03:26 AM


Group: Member
Posts: 572

https://www.clinuvel.com/social-media/subq/...iness-execution
  Forum: By Share Code

odi01
Posted on: Dec 7 2018, 04:16 PM


Group: Member
Posts: 572

https://www.fool.com.au/2018/12/07/3-small-...to-buy-today-2/
  Forum: By Share Code

odi01
Posted on: Dec 7 2018, 04:14 PM


Group: Member
Posts: 572

https://www.fool.com.au/2018/12/07/why-the-...up-111-in-2018/
  Forum: By Share Code

odi01
Posted on: Dec 5 2018, 03:15 AM


Group: Member
Posts: 572

https://finance.yahoo.com/news/avita-medica...-074600689.html
  Forum: By Share Code

odi01
Posted on: Dec 4 2018, 07:27 PM


Group: Member
Posts: 572

https://www.change.org/p/licht-f%C3%BCr-all...amp;utm_term=cs

Please also sign for James in England! Please sign for James!

4. DEC. 2018 —

Please sign for James!

EPP patients in England fear that they will not get access to Afamelanotide - although it is the only therapy!

The reason for this is the scandalous situation at the NICE (National Institute for Health and Care Excellence), which decides which therapies should be available in England - and which not. In the case of EPP, for example, the responsible representatives of the authority simply claim that the therapy has only a minimal benefit. However, the authority ignores the fact that the efficacy has been demonstrated in several large clinical trials and, even worse, it simply ignores the experiences of those affected: EPP patients have repeatedly stressed the life-changing effects of the treatment during negotiations with the authorities. Numerous German patients have also submitted impressive statements and described the disease but also the effect of the treatment, but NICE still remained negative. It is also frightening that the responsible representatives of the authority expressed the opinion in a public meeting that EPP does not represent any restriction - "one would not look at the patient externally".

The International Porphyria Patient Network (IPPN), which I co-founded, supports British patients in the negotiations. In July, together with other complainants at a public meeting, I discussed the matter with the decision-makers and criticised the rejection of the therapy. The independent committee that judged the objections raised proved us right in several respects - among other things, the efficacy of the therapy cannot be rated as "small". In addition, EPP should be seen as a massive restriction (see also last update). The evaluation is now being reopened - but again NICE has the last word and we can only hope that the patients and our arguments are actually taken seriously now.

James lives in England and is directly affected by the outcome of the negotiations. His mother, Claire Creag, has launched a petition on change.org. Please also support your James so that he and all EPP patients in the UK can soon have access to Afamelanotide and lead a normal life without fear of light and burning pain:

https://www.change.org/p/theresa-may-mp-fun...phyria-patients


https://www.nice.org.uk/guidance/indevelopm...10009/documents
  Forum: By Share Code

odi01
Posted on: Dec 2 2018, 04:28 AM


Group: Member
Posts: 572

https://www.change.org/p/theresa-may-mp-fun...phyria-patients
  Forum: By Share Code

odi01
Posted on: Nov 27 2018, 12:35 AM


Group: Member
Posts: 572

http://www.clicmedicina.it/porfirie-luce-sole/

Porphyria: when sunlight scares you

Porphyria is a group of rare and little-known hereditary metabolic diseases linked to a deficiency of one of the different enzymes in the heme metabolic chain. The variety of their symptoms makes them particularly complicated to diagnose: they are characterized by neurological manifestations (called neurovisceral attacks), skin lesions due to photosensitivity or the combination of the two.

"The main problem for patients is political and administrative: we need models of care adapted to the uniqueness of the disease," explains Dr. Gerardo Tiso. "A clear, transparent and homogeneous diagnostic and therapeutic path is essential throughout the country, for chronic and acute porphyria. For erythropoietic protoporphyria, the needs to be urgently considered are the insufficiency of treatments in place and their geographical disparity. For patients with acute porphyria, on the other hand, one of the great problems is that of being treated by experienced people when they appear in the emergency rooms of our hospitals: they live with the fear of suffering irreparable damage and have difficulty in relating to the doctors on duty.

Fortunately, for these diseases, research is progressing: "At the moment, the development of new very promising drugs for the treatment of patients with acute porphyria is proceeding and phase three studies with gyrosivan are underway," says Prof. Paolo Ventura. "Also for erythropoietic protoporphyria today there is a drug, called afamelanotide, which is implanted under the skin at the iliac crest under local anesthesia," adds Dr. Luca Barbieri, of the Center for Porphyria and Rare Diseases of the San Gallicano Dermatological Institute IFO IRCCS in Rome.

For these diseases, since 2016 is active the association named after Domenico Tiso, pediatrician from Livorno great expert in porphyria, from which the same doctor was affected.

Translated with www.DeepL.com/Translator
  Forum: By Share Code

odi01
Posted on: Nov 27 2018, 12:18 AM


Group: Member
Posts: 572

https://www.dasinvestment.com/mischfonds-pl...s-auf-der-spur/

However, Clinuvel Pharmaceuticals from Melbourne, Australia, is number 1 in the portfolio and its share price roughly doubled in the third quarter.
  Forum: By Share Code

odi01
Posted on: Nov 16 2018, 03:38 PM


Group: Member
Posts: 572

BUZZ-Australia's Avita Medical climbs after commencing Recell deliveries
reuters.com · 16.11.2018, 03:52:48
** Shares of regenerative medicine company Avita Medical Ltd rise as much as 9.88 pct to A$0.089, their highest in a week
** Stock posts its biggest intraday pct gain since Oct. 18
** Company says https://bit.ly/2QR1agJ 32 U.S. burns centres have commenced ordering and taking deliveries of its Recell System
** Company also completes hiring of the U.S. sales team to support the U.S. market launch of the Recell System
** Avita Medical received U.S. FDA approval for its Recell system in September
** Avita's Recell system is a device used to treat severe thermal burn injuries using the patient's own skin samples
** Stock had risen 28.6 pct this year, as of last close
  Forum: By Share Code

odi01
Posted on: Nov 16 2018, 04:37 AM


Group: Member
Posts: 572

https://www.informa.com.au/event/conference...ions-australia/


Speakers

Nicoletta Muner
Director, Global Regulatory Affairs', CLINUVEL PHARMACEUTICALS
  Forum: By Share Code

odi01
Posted on: Nov 15 2018, 04:46 PM


Group: Member
Posts: 572

https://mobile.twitter.com/ClinuvelNews/sta...714278245916672
  Forum: By Share Code

odi01
Posted on: Nov 13 2018, 12:55 AM


Group: Member
Posts: 572

https://vis2018.org/sponsorship/
  Forum: By Share Code

odi01
Posted on: Nov 12 2018, 03:11 AM


Group: Member
Posts: 572

Wrong direction

Kräuter demanded more nursing and medical staff, regular supervision, spatial improvements and an end to fixations in multi-bed rooms: "These are unacceptable." Kräuter sees a "change" in child and youth welfare that is going in the wrong direction: Different regulations would worsen the situation.

Moreover, it is still not clear why in Styria, after Vienna, most of the children are accommodated in other places, and one has to get to the bottom of this. Social Councillor Doris Kampus (SPÖ) has already announced an investigation, which he welcomes. Kräuter also warned against refusing medical treatment on cost grounds. He mentioned the case of a Styrian who suffers from the so-called shadow-jumper disease.

About 60 patients are known throughout Austria. According to the Ombudsman, the costs for a drug available since 2014 amount to about 60,000 euros per year. While the medicine was approved for two other patients, the KAGes rejected the treatment of the Styrian with the medicine. In a statement to the Ombudsman's Office, the KAGes compared the "additional benefit of the medication with the costs to be incurred". "You must never come up with cost arguments when it comes to pain," said Kräuter.

.......
About 60 patients are known throughout Austria


https://mobil.derstandard.at/2000087129208/...emeindefusionen
  Forum: By Share Code

odi01
Posted on: Nov 12 2018, 03:03 AM


Group: Member
Posts: 572

SHADOW JUMPING DISEASE - WHO PAYS FOR THE THERAPY?


Shadow Jumping Disease or Erythropoietic Protoporphyria (EPP) is the name of the rare disease from which a Styrian suffers. In order to alleviate his suffering, he needs a medication that is neither paid for by the regional health insurance fund nor by the hospital operator.

A Styrian suffers from the so-called shadow-jumper disease. The very rare genetic metabolic disease manifests itself in painful sensitivity to light. Despite the protection of long clothes, gloves and scarves, a prolonged stay in the sun leads to severe pain on the skin. The number of people affected is low. Experts speak of just over 30 people in Austria.

The only effective medication in the case of the Styrian is called Scenesse. Scenesse is injected into the hospital in the form of an implant and costs around 14,000 euros per treatment. Depending on the number of treatments, the costs amount to around 60,000 to 80,000 euros per year. Health insurance companies and hospital owners consider the other to be obliged to pay for the treatment.

In the ORF programme "Bürgeranwalt", Volksanwalt Kräuter explains how this lack of clarity about bearing the costs arises. In Austria, the drug is administered exclusively in two clinics. According to the Main Association of Social Insurance Institutions, the costs of treatment in hospitals are borne by the hospital operator or the state funds. The hospital operator in turn believes that this type of outpatient treatment would justify cost coverage by the regional health insurance funds.

"The patient becomes again once the play ball of the authorities and remains with its suffering on the distance! It cannot be that the costs for a patient are carried by the hospital and with the next not!

Ombudsman G?nther herbs demands clear authority structures, so that the citizens and citizens are not exposed to an authority arbitrariness. The public prosecutor's office will strive for a renewed examination of the individual case with the hospital carrier


http://volksanwaltschaft.gv.at/artikel/sch...lt-die-therapie
  Forum: By Share Code

odi01
Posted on: Nov 9 2018, 03:45 AM


Group: Member
Posts: 572


EPP at the World Congress in Barcelona


8TH NOV. 2018 —

Although Afamelanotide is approved in the EU, most EPP patients have no or only limited access: After approval, national authorities in each individual EU country re-evaluate the documentation and decide whether the drug should also be available in that country. This can make sense if several existing therapies are to be compared with each other. It becomes problematic, as in our case, when it comes to the first and only treatment. Then these additional assessments often lead to years of delays in access or, in the worst case, even to negative decisions - although there is no alternative!

EPP patients from Germany, Italy and Switzerland are using the example of the national assessment of afamelanotide in England to draw attention to this absurd situation at the European World Congress on Medicinal Products for Rare Diseases in Barcelona.



https://www.change.org/p/licht-f%C3%BCr-all...amp;utm_term=cs
  Forum: By Share Code

odi01
Posted on: Nov 2 2018, 06:43 PM


Group: Member
Posts: 572

http://www.time.com/5442802/palau-sunscreen-ban-coral-reef/
  Forum: By Share Code

odi01
Posted on: Oct 18 2018, 04:09 PM


Group: Member
Posts: 572

https://www.businesswire.com/news/home/2018...LL%C2%AE-System
  Forum: By Share Code

odi01
Posted on: Oct 17 2018, 05:30 AM


Group: Member
Posts: 572

https://www.businesswire.com/news/home/2018...um-Presentation
  Forum: By Share Code

odi01
Posted on: Oct 13 2018, 12:05 AM


Group: Member
Posts: 572

https://www.change.org/p/ein-leben-ohne-son...amp;utm_term=cs
  Forum: By Share Code

odi01
Posted on: Oct 11 2018, 04:24 PM


Group: Member
Posts: 572

https://kalkinemedia.com/2018/10/10/clinuve...ion-in-england/
  Forum: By Share Code

odi01
Posted on: Oct 10 2018, 07:12 PM


Group: Member
Posts: 572

https://www.finnewsnetwork.com.au/archives/...work200884.html
  Forum: By Share Code

odi01
Posted on: Oct 10 2018, 05:42 PM


Group: Member
Posts: 572

https://www.change.org/p/ein-leben-ohne-son...amp;utm_term=cs
  Forum: By Share Code

odi01
Posted on: Oct 7 2018, 09:45 PM


Group: Member
Posts: 572

https://www.gofundme.com/prayers-for-krysztian-groom


https://ktxs.com/news/nation-world/6-year-o...ing-set-on-fire
  Forum: By Share Code

odi01
Posted on: Oct 7 2018, 07:28 PM


Group: Member
Posts: 572

https://clinicaltrials.gov/ct2/show/NCT0362...recrs=abdefghim
  Forum: By Share Code

odi01
Posted on: Oct 7 2018, 06:33 PM


Group: Member
Posts: 572

https://foxillinois.com/news/local/6-year-o...dure-10-05-2018
  Forum: By Share Code

odi01
Posted on: Oct 7 2018, 06:23 PM


Group: Member
Posts: 572

https://www.smh.com.au/money/investing/dine...005-p507x1.html
  Forum: By Share Code

odi01
Posted on: Oct 4 2018, 07:06 PM


Group: Member
Posts: 572

https://eu.vcstar.com/story/news/local/comm...ent/1449404002/
  Forum: By Share Code

odi01
Posted on: Oct 4 2018, 05:48 PM


Group: Member
Posts: 572

https://www.baseballdailydigest.com/2018/09...fitzgerald.html
  Forum: By Share Code

odi01
Posted on: Oct 4 2018, 01:08 AM


Group: Member
Posts: 572

https://www.nasdaq.com/press-release/nasdaq...-20180928-00518


https://edge.media-server.com/m6/p/34dvbwgm...970/st/clinuvel
  Forum: By Share Code

odi01
Posted on: Sep 30 2018, 03:59 AM


Group: Member
Posts: 572

https://www.smh.com.au/money/investing/elli...928-p506kx.html
  Forum: By Share Code

odi01
Posted on: Sep 30 2018, 02:43 AM


Group: Member
Posts: 572

https://www.change.org/p/9945077/u/23341035...59882&jb=41

29. SEP. 2018 -

In the episode 156 of "In der Freundschaft", the photodermatitis EPP (erythropoietic protoporphyria) and the treatment with afamelanotide are depicted in great detail! The attentive doctors even think to turn off the lights in the room, as the artificial light could harm their patient.

Informing people about EPP via popular media is extremely important and helpful because many sufferers still receive the correct diagnosis very late in life and often are not taken seriously in their own needs. Therefore, a big thank you to the sensitized for rare diseases young medical profession Sachsenklinik;)
  Forum: By Share Code

odi01
Posted on: Sep 28 2018, 05:04 PM


Group: Member
Posts: 572

https://finance.nine.com.au/2018/06/25/18/4...w-drug-scenesse
  Forum: By Share Code

odi01
Posted on: Sep 22 2018, 03:07 PM


Group: Member
Posts: 572

https://scrip.pharmaintelligence.informa.co...n-Drug-Scenesse
  Forum: By Share Code

odi01
Posted on: Sep 14 2018, 12:28 PM


Group: Member
Posts: 572

http://martinshkreli.com



Sorry I haven’t posted in a while. I was (and still am) busy reading about rare diseases.........???
  Forum: By Share Code

odi01
Posted on: Sep 14 2018, 02:53 AM


Group: Member
Posts: 572

https://www.basellife.org/basel-life-2018/b...bal-health.html

12.45
Developing new products for vulnerable populations in high income countries – the case of erythropoeitic protoprophyria
Jasmin Barman-Aksözen (Stadtspital Triemli, Zurich, Switzerland
  Forum: By Share Code

odi01
Posted on: Aug 29 2018, 03:48 PM


Group: Member
Posts: 572

https://expansion.mx/tendencias/2018/08/28/...roteccion-solar
  Forum: By Share Code

odi01
Posted on: Aug 23 2018, 01:17 AM


Group: Member
Posts: 572

https://clinuvel.us19.list-manage.com/track...mp;e=40713266c1
  Forum: By Share Code

odi01
Posted on: Aug 21 2018, 12:39 PM


Group: Member
Posts: 572

https://kalkinemedia.com/2018/08/21/5-austr...yp-tlx-and-bot/
  Forum: By Share Code

odi01
Posted on: Aug 8 2018, 11:48 PM


Group: Member
Posts: 572

https://www.instagram.com/p/BmOE0YDjbUF/?ut...d=1mc5yuy4qldql
  Forum: By Share Code

odi01
Posted on: Aug 1 2018, 01:09 PM


Group: Member
Posts: 572

https://stockhead.com.au/health/us-roadbloc...velopments/amp/
  Forum: By Share Code

odi01
Posted on: Aug 1 2018, 04:42 AM


Group: Member
Posts: 572

https://www.sat1.de/tv/endlich-feierabend/v...m-schatten-clip
  Forum: By Share Code

odi01
Posted on: Jul 20 2018, 10:41 PM


Group: Member
Posts: 572

https://www.cnn.com/2018/07/20/health/sunsc...pill/index.html
  Forum: By Share Code

odi01
Posted on: Jul 17 2018, 04:23 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...;idsId=02000189
  Forum: By Share Code

odi01
Posted on: Jul 4 2018, 02:50 PM


Group: Member
Posts: 572

https://www.asx.com.au/asx/statistics/displ...=pdf&idsId=
  Forum: By Share Code

odi01
Posted on: Jul 3 2018, 02:43 PM


Group: Member
Posts: 572

https://finfeed.com/features/sun-shines-sma...s-are-battered/
  Forum: By Share Code

odi01
Posted on: Jul 3 2018, 02:19 AM


Group: Member
Posts: 572

https://youtu.be/lLkLuc8rUUw
  Forum: By Share Code

odi01
Posted on: Jun 28 2018, 03:34 PM


Group: Member
Posts: 572

https://www.dermatologyadvisor.com/general-...article/776688/
  Forum: By Share Code

odi01
Posted on: Jun 26 2018, 02:54 AM


Group: Member
Posts: 572

https://www.onvista.de/news/original-resear...h-buy-103926105
  Forum: By Share Code

odi01
Posted on: Jun 26 2018, 02:43 AM


Group: Member
Posts: 572

http://www.more-ir.de/d/16649.pdf
  Forum: By Share Code

odi01
Posted on: Jun 25 2018, 07:36 PM


Group: Member
Posts: 572

https://www.minussinus.de/2018/06/25/clinuv...19-zu-erwarten/


Clinuvel Pharmaceuticals announced last night that it has submitted the regulatory filings for its Scenesse drug to the US Food and Drug Administration (FDA). By the end of August, the FDA will decide whether to apply a Priority Review; after that it takes 6-10 months to reach the final decision. This means that US approval is expected from the beginning of March to the end of June 2019!

The details of the announcement can be found here:

https://www.asx.com.au/asxpdf/20180625/pdf/...0mgrl4csb10.pdf

After a number of delays in recent years, this is one of the first important events Clinuvel has kept his word for - a clear indication that both the maturity of the Scenesse product and that of the management and organization over the years have come to an end Time has increased significantly.

The next few months remain eventful: at the end of July there will be quarterly figures for Q4 2017/18 (ending on 30.06.2018) - here I expect record sales and cash flows by expanding the treatment of EPP patients, especially in Germany (Ramp-up of the treatment center Dusseldorf) and Switzerland (where meanwhile all patients in need of treatment have confirmed reimbursements by the health insurance).

In addition, there is still the announced topical product line before publication, so a preparation that acts by applying over the skin. I remain skeptical as to whether this can really be a product that contains afamelanotide as an active ingredient (since the molecule is very large and barely able to cross the skin barrier), but it will certainly give an indication of where the company is heading would like to develop.

Today is fittingly World Vitiligo Day, on the occasion of a conference in the United States takes place. Clinuvel is also active as a sponsor. Anyone interested in the condition of vitiligo, the state of research and treatment options for patients should refer to the book by Yan Valle, the CEO of the American Vitiligo Research Foundation:

Regarding my rating, nothing fundamental changes, I stay with a target price of 21-24 EUR. With a successful NDA decision, I would probably lower the cost of equity because of the lower risk, and that would lead to a much higher valuation.


  Forum: By Share Code

odi01
Posted on: Jun 25 2018, 02:17 PM


Group: Member
Posts: 572

https://www.fool.com.au/2018/06/25/why-the-...ocketing-today/
  Forum: By Share Code

odi01
Posted on: Jun 25 2018, 03:40 AM


Group: Member
Posts: 572

NEW TO THE PETITION
Do not be afraid of the summer
Swiss Society for Porphyry - www.porphyria.ch
JUNE 24, 2018 - The summer is here and, fortunately, all Swiss EPP patients who require afamelanotide have received the reimbursement of the treatment from their health insurers. We can thus look forward to the summer with much less fear of painful phototoxic reactions and enjoy it together with partners, family and friends. After many challenges and with the help of many supporters we are very happy to have reached this goal ... for this year ... because we still live with the uncertainty about whether or not we will be provided with this therapy in the long term and sustainably - Unfortunately, there is a systemic error in the annual and arbitrary case-by-case decisions - Policy and competent authorities are still called upon to remedy this systemic error and eliminate this treatment bias against those affected by rare diseases. This also means that we will continue to fight to bring about these much-needed changes in our health care system!

Andreas Wildi, SGP lawyer, has written a very good article in the NZZ on this problem (see link) - worth reading!

With sincere wishes for a healthy, painless and beautiful summer!

https://www.change.org/p/6935921/u/22923864...259882&jb=7
  Forum: By Share Code

odi01
Posted on: Jun 23 2018, 12:34 AM


Group: Member
Posts: 572

https://ih.advfn.com/stock-market/USOTC/cli...-pc-CLVLY/chart
  Forum: By Share Code

odi01
Posted on: Jun 19 2018, 02:35 AM


Group: Member
Posts: 572

June 2018

Sun full of summer ....... More and more patients are starting to enjoy it thanks to the treatment. It is even more important that patients without treatment receive such a treatment in order not to suffer anymore and that a care concept is developed for children and adolescents.

http://www.epp-deutschland.de/index.html
  Forum: By Share Code

odi01
Posted on: Jun 18 2018, 12:15 PM


Group: Member
Posts: 572

https://stockhead.com.au/health/ma-watch-wh...ech-sector/amp/
  Forum: By Share Code

odi01
Posted on: Jun 14 2018, 03:04 PM


Group: Member
Posts: 572

Tucson Tech: UA licenses drugs to help prevent skin cancer The University of Arizona is moving to commercialize two faculty-invented drug compounds that could help protect people from sun damage and skin cancer by boosting the skin’s natural pigment. The chemical compounds, developed by professors Minying Cai and Victor Hruby in the UA department of chemistry and biochemistry, were recently licensed to startup MCR Therapeutics, formed by Cai and Hruby last year. Hruby is a regents professor emeritus who has been involved in several drug startups, and Cai is a longtime drug researcher who joined the UA in 1999 as a research scientist and has been a research professor since 2007. Each hold appointments in the College of Science and the College of Medicine and are members of the Arizona Cancer Center and the UA Bio5 Institute. The peptides developed by Cai and Hruby target certain melanocortin receptors, which stimulate the natural production of skin cells that produce melanin — the pigment responsible for skin color that provides protection against harmful ultraviolet light. With 3 million new cases diagnosed each year, skin cancer is one of the most common and deadly cancers. More than 9,300 people are expected to die from the disease in 2018 in the U.S. alone. The new drugs could help protect people from skin cancer as a more effective alternative to traditional sunscreens. Sunscreen lotions can prevent skin damage from ultraviolet radiation, but they are often applied incorrectly, can easily wash away and are only partially effective compared to natural tanning or pigmentation, Hruby said. Drugs based on the new peptides could be administered via a nasal spray, intraperitoneal injection into the body cavity or perhaps a skin patch, Hurby said. Though the peptides have shown promise in preclinical studies, they would still need to go through a series of human clinical trials to win regulatory approval. Hruby said he and Cai are talking with two companies about partnering or collaborating with them to push the research forward. “We think were within one or two years of clinical trials, all we have to do is get a partner to do the necessary things with the FDA,” he said. Melanocortin receptors are known to play a role in other physiological aspects such as obesity, stress, cognition and mood, but MCR plans to initially focus on skin. Cai and Hruby have worked together for years on drugs that target melanocortin receptors. In 2016, the pair licensed a startup company to develop a drug that showed promise in treating acute depression and related ailments by blocking the receptors. And this isn’t the first time Hruby has shepherded a melanin-boosting drug to market. In the 1980s, Hruby and another UA professor, the late Mac Hadley, invented a skin-darkening compound, afamelanotide, later known as Melanotan I, that was licensed to an Australian company. The company, now known as Clinuvel, won European approval of the drug labeled as Scenesse to treat patients with erythropoietic protoporphyria, a rare disease that causes severe inflammation of the skin with exposure to sunlight. A related drug known as Melanotan II is widely and illegally sold on the internet as an injectable tanning agent sometimes called the “Barbie drug.” It is banned in the U.S., Canada and Europe because it has not undergone proper testing and is known to cause serious side effects. Hruby said the new peptides he and Cai have developed differ from the earlier compounds because they are selective in their action and hence don’t cause problematic side effects. The research team worked with Tech Launch Arizona, the office of the UA that commercializes inventions stemming from UA research, to patent the technologies and advanced their business plan through the National Science Foundation I-Corps program. They also received TLA asset-development funding to help ready their product for market.

  Forum: By Share Code

odi01
Posted on: Jun 14 2018, 02:41 PM


Group: Member
Posts: 572


Tucson Tech: UA licenses drugs to help prevent skin cancer
Arizona Daily Star-vor 2 Stunden
The company, now known as Clinuvel, won European approval of the drug labeled as Scenesse to treat patients with erythropoietic

Site locked for Europe
  Forum: By Share Code

odi01
Posted on: Jun 14 2018, 02:31 PM


Group: Member
Posts: 572

https://tucson.com/business/tucson-tech-ua-...23e3c96ec1.html
  Forum: By Share Code

odi01
Posted on: Jun 14 2018, 04:19 AM


Group: Member
Posts: 572

Updated28 July 2014



https://www.smh.com.au/business/clinuvel-re...0728-zxlj6.html
  Forum: By Share Code

odi01
Posted on: Jun 6 2018, 04:04 PM


Group: Member
Posts: 572

Clinuvel Pharmaceuticals Limited (ASX: CUV)

No well-diversified Gen Y share portfolio would be complete without a biotech company, and while most will consider CSL Limited (ASX: CSL) to be on the expensive side, emerging players like Clinuvel Pharmaceuticals could be a consideration.

This $570 million market cap company appears to be kicking goals of late, with its focus on drugs for severe skin disorders gaining traction as Clinuvel manages to report positive cash flow of $230,000 for the quarter ending March 31, 2018, despite continued research and development efforts for its novel drug SCENESSE.

Clinuvel looks to operate in a financially disciplined manner and labels itself a “pioneer” in the photomedicine space.

One to watch for sure.
  Forum: By Share Code

odi01
Posted on: Jun 6 2018, 03:58 PM


Group: Member
Posts: 572

https://www.fool.com.au/2018/06/06/5-under-...on-y-investors/
  Forum: By Share Code

odi01
Posted on: May 28 2018, 10:11 PM


Group: Member
Posts: 572

In Germany, around 800 people are registered. Experts believe that many more are not yet diagnosed, because even doctors often do not know the disease and therefore misinterpret signs. "The biggest problem was that you did not know my illness," complains Braun. Like all sufferers, she was desperately searching for years for the cause of her pain. She often met with incomprehension, nobody believed her.
  Forum: By Share Code

odi01
Posted on: May 16 2018, 11:36 PM


Group: Member
Posts: 572


Eu tenho vitiligo, e daí?
VEJA.com-11.05.2018
O Scenesse, como foi batizado pelo fabricante, o laboratório australiano Clinuvel, libera afamelanotide, um composto que ativa a célula ...


https://veja.abril.com.br/revista-veja/eu-t...vitiligo-e-dai/
  Forum: By Share Code

odi01
Posted on: May 15 2018, 02:53 PM


Group: Member
Posts: 572

http://barman.de/Eurordis_poster_05_2018_dechant.pdf
  Forum: By Share Code

odi01
Posted on: May 15 2018, 02:46 PM


Group: Member
Posts: 572

https://www.change.org/p/9945077/u/22746830...59882&jb=43
  Forum: By Share Code

odi01
Posted on: May 7 2018, 05:30 AM


Group: Member
Posts: 572

http://www.watoday.com.au/money/investing/...504-p4zdef.html biggrin.gif
  Forum: By Share Code

odi01
Posted on: May 4 2018, 02:56 AM


Group: Member
Posts: 572

http://clinuvel.com/social-media/subq/slip-slop-slap
  Forum: By Share Code

odi01
Posted on: May 2 2018, 04:18 AM


Group: Member
Posts: 572

Epp Youtube Chanel

https://www.youtube.com/channel/UCEQZAj_4gHTJYxDW79zGX_Q
  Forum: By Share Code

odi01
Posted on: Apr 30 2018, 07:52 PM


Group: Member
Posts: 572

https://www.change.org/p/6935921/u/22694682...259882&jb=7
  Forum: By Share Code

odi01
Posted on: Apr 28 2018, 12:41 AM


Group: Member
Posts: 572

https://youtu.be/IyyOJ3B3UUk

Porphyria Awareness Week 2018
  Forum: By Share Code

odi01
Posted on: Apr 27 2018, 11:58 PM


Group: Member
Posts: 572

https://www.instagram.com/p/BiEzf5UBTgs/?r=wa1
  Forum: By Share Code

odi01
Posted on: Apr 27 2018, 01:19 PM


Group: Member
Posts: 572

https://www.fool.com.au/2018/04/27/2-asx-li...-excited-about/
  Forum: By Share Code

odi01
Posted on: Apr 26 2018, 06:19 PM


Group: Member
Posts: 572

new investors ?

DFA Asia Pacific Small Company Series 30.56K 0.06% 0 0.01% 01/31/18
Smith & Williamson Unit Trusts - Oriental Growth Fund 30.44K 0.06% 0 1.03% 01/31/18
Dimensional Fund Advisors LP 41.84K 0.09% 9.53K 0% 01/31/18


http://www.barrons.com/quote/stock/us/ootc/clvly
  Forum: By Share Code

odi01
Posted on: Apr 25 2018, 12:00 AM


Group: Member
Posts: 572

https://www.instagram.com/p/Bh9IidMhLIh/?r=wa1
  Forum: By Share Code

odi01
Posted on: Apr 21 2018, 12:05 AM


Group: Member
Posts: 572

https://www.instagram.com/p/BhyxjITg7iL/?r=wa1

https://www.instagram.com/p/BhyPBsqATls/?r=wa1
  Forum: By Share Code

odi01
Posted on: Apr 20 2018, 05:02 PM


Group: Member
Posts: 572

Takeda, I hope not, Takeda already took me Ariad Pharmaceuticals
  Forum: By Share Code

odi01
Posted on: Apr 19 2018, 08:08 PM


Group: Member
Posts: 572

The Handelsblatt is the highest-circulation German-language business and financial newspaper. It has around 200 editors and correspondents worldwide. With a circulation of 125,860 copies sold, the Handelsblatt reaches more than half a million readers daily (AWA 2012). [10] The Handelsblatt is the most cited economic medium in Germany (Media Tenor, 2004-2011).

https://de.m.wikipedia.org/wiki/Handelsblatt
  Forum: By Share Code

odi01
Posted on: Apr 19 2018, 07:57 PM


Group: Member
Posts: 572

http://www.handelsblatt.com/finanzen/anlag...en/8846146.html


Trader Christoph Neemann trades in his Wikifolio "Minus Sinus Value Select" shares, which in his opinion have a sufficient distance to the fair value, the so-called "Margin of Safety" exhibit. What is important for him is that he buys shares from companies whose business model and risks he can assess. For his trading idea, Neemann reserves the right to implement them with ETFs or funds. He waives leveraged products.

Given the prevailing market conditions, Neemann concentrates on a few stocks that he singles, as in the case of Clinuvel (plus 47 percent since purchase), relatively high weighted. Since its creation in September 2016, the Wikifolio has achieved a plus of 50 percent with a maximum loss of 13.4 percent. The index value of Wikifolios has grown three times faster compared to the MSCI World Index. Investors have invested in the associated Wikifolio index certificate so far about 11,000 euro
  Forum: By Share Code

odi01
Posted on: Apr 18 2018, 07:46 PM


Group: Member
Posts: 572

18th APR. 2018 - Good report followed by a conference talk with the cardiologist and EPP patient dr. Cornelia Dechant on Austrian Radio ORF 2 on the situation of Austrian patients. Dr. Dechant advocates access to afamelanotide for all those affected in Austria and addresses the challenges and treatment in Austria. Report and design: Sonja Hochecker. With the participation of the Swiss Society of Porphyria.


https://www.change.org/p/9945077/u/22649013...59882&jb=43
  Forum: By Share Code

odi01
Posted on: Apr 11 2018, 11:41 PM


Group: Member
Posts: 572

https://www.wallstreet-online.de/nachricht/...-abstand-halten

Class instead of mass

Given the prevailing market conditions, Neemann concentrates on a few stocks that he singles, as in the case of Clinuvel (+47 percent since purchase), relatively high weighted.
  Forum: By Share Code

odi01
Posted on: Apr 8 2018, 12:33 AM


Group: Member
Posts: 572

Pluto continues to grow, from 4.12% to 4.82%

https://www.plutos.de/plutos-multi-chance-fund/
  Forum: By Share Code

odi01
Posted on: Mar 22 2018, 05:10 PM


Group: Member
Posts: 572

https://drive.google.com/file/d/1qf4Qwjg8sM...iew?usp=sharing
  Forum: By Share Code

odi01
Posted on: Mar 22 2018, 05:02 PM


Group: Member
Posts: 572

http://www.policlinico.mi.it/uploads/fom/a...ta_clinuvel.pdf
  Forum: By Share Code

odi01
Posted on: Mar 19 2018, 12:55 AM


Group: Member
Posts: 572

Good Postings in Germany

https://www.wallstreet-online.de/diskussion...maceuticals-ltd
  Forum: By Share Code

odi01
Posted on: Mar 18 2018, 05:30 AM


Group: Member
Posts: 572

https://www.zoominfo.com/p/Daniela-Schaefer/1822170687
  Forum: By Share Code

odi01
Posted on: Mar 18 2018, 05:27 AM


Group: Member
Posts: 572

http://www.thepictaram.club/p/clinuvel

Fron Wallstreet online. de
Thanks Walltrader2014
  Forum: By Share Code

odi01
Posted on: Mar 9 2018, 12:49 AM


Group: Member
Posts: 572

MARCH 8, 2018 - On the day of the rare diseases organized by Proraris and the Inselspital in Bern on March 3, 2018, Dr. Ing. Rocco Falchetto, President of the Swiss Society of Porphyria, gave an interesting update on the situation regarding compensation of afamelanotide in a short presentation. You can see the video of it on this Vimeo link:

http://vimeo.com/258424697


https://www.change.org/p/6935921/u/22479655...259882&jb=7
  Forum: By Share Code

odi01
Posted on: Mar 4 2018, 04:46 PM


Group: Member
Posts: 572

From wallstreet-online.de

https://m.jobsdb.com/en-sg/search.do?JSRV=1...amp;JSSRC=SRLSC

VALLAURIX PTE. LTD. The selected candidate will join a global biopharmaceutical company focused on developing drugs for the treatment of a range of disorders. The company has identified patient populations with specific clinical needs. Personal Assistant to Director 02-Mar-18 jobsDB Ref. JSG400003003540618 Employer Ref. 6330498 We are looking for a responsible Personal Assistant to provide personalized secretarial and administrative support in a well-organized and timely manner. You will work on a one-to-one basis on a variety of tasks related to manager’s working life and communication. Position open to Singaporean only. Career Level:Entry Level Yr(s) of Exp:3 years Qualification: Diploma Industry: Accounting / Audit / Tax Services Job Function: Professional Services > Company Secretary Zonal Segregation: No Fixed Location Salary:Salary provided Employment Type: Full Time

  Forum: By Share Code

odi01
Posted on: Feb 28 2018, 08:56 PM


Group: Member
Posts: 572

https://www.change.org/p/ein-leben-ohne-son...utm_term=266724

Rare Disease Day - Journée des maladies rare - Giornata delle malattie rare
Swiss Society for Porphyry - www.porphyria.ch
28th FEB. 2018 - On the occasion of the Rare Disease Day, Triemli City Hospital highlights an EPP article published recently in the GlücksPost: "When light hurts" - we look forward to seeing you all!
We continue to fight for treatment justice among EPP patients and other rare disease sufferers!
  Forum: By Share Code

odi01
Posted on: Feb 28 2018, 08:50 PM


Group: Member
Posts: 572

https://www.glueckspost.ch/gesundheit/wenn-licht-wehtut/


Erythropoietic protoporphyria
When light hurts
Low-light months like January are a relief for people who suffer from light sickness. Because then they have more time to go outside without harming them.

A beautiful winter landscape, snow and sunshine - for the molecular biologist Dr. Jasmin Barman (38) was a scary idea for most of her life. Your skin can not tolerate the sun's rays. Like fire under the skin, it feels like it's going to be exposed to the sun too long anyway. And too long can be a few minutes.

Erythropoietic protoporphyria (EPP) is the name given to the condition associated with such symptoms. A metabolic disorder where the production of red blood pigment does not work properly. Jasmin Barman has been suffering since early childhood. Even as a baby she cried when she was exposed to the sun - why, nobody knew then. A sun or light allergy was finally accepted - but with an allergy the whole thing has nothing to do. Also psychological reasons were suspected, and not infrequently it was also suspected of the simulation. It took decades for her to come to grips with her illness, especially through her own persistent research. Today she is researching her at the Triemlispital in Zurich.

Pain under the skin

EPP is one of the rare diseases - it affects about one in every 100,000 people. It is estimated that around 80 people in Switzerland suffer from it. In light, an inflammatory reaction develops under her skin, causing a massive pain in the chest. Even body heat from other people is then very painful for those affected, so children push their parents away when they want to take comforting in their arms. "At night, you can not sleep because your own body heat is so painful," says Dr. Barman.

Sunscreens are practically ineffective in EPP, because not the UV radiation causes the problem, but the visible light, especially the blue parts. And when it fires under the skin, and the pain is almost unbearable, painkillers do not help: "You just have to endure the pain." And to prevent, by avoiding the sun, avoid covering the skin with light. A special umbrella, which reflects the sun on the outside and absorbs the rays inside, which in spite of everything gets under the umbrella from the side, was the constant companion of Jasmin Barman for many years. Today she does not always have him with her. Because there is now a drug that allows EPP sufferers a nearly "normal" life! What that means, can only be measured by someone who has experienced it himself. "It's like a new life," says Jasmin Barman.

Dangerous energy-saving lamps

In the beginning she could hardly believe it herself. "I was very skeptical," she says. At first she ventured into the sun for only a few minutes, carefully feeling her way to the new freedom. Then she became more courageous. Although she has never ventured into a swimming pool until now, and on the bus she knows exactly where she sits down best. But by now she has even fulfilled her dream of seeing the sequoias in California: "In August 2015, my husband and I made a wonderful trip through the United States. That would have been unthinkable without the treatment. "

Every two months, Jasmin Barman needs a dose of the drug that is implanted and the carrier dissolves itself after the drug is released. In the winter she even gets by without. "However, I know sufferers who are very sensitive to artificial light sources - especially the light of the new energy-saving light bulbs is very dangerous for us," she says. "Some patients need protection around the year."

However, quite a few people still do not get it - a Swiss health insurance company has not yet paid the costs. "We hope that even the last fund will soon enable their patients to live almost normally with light and joy in the bright season", explains Dr. med. Barman. Not to experience sunlight as an enemy, but to be able to enjoy all the positive aspects that it has for the mind - this happiness would like to treat all those affected: «Just feel the warmth of the sun on the skin and a bright day To be happy instead of having to be afraid of pain, that is so much quality of life and freedom - not just for me, but for my whole environment. »

WHAT IS EPP?
Erythropoietic protoporphyria is a metabolic disorder based on a rare genetic defect that affects blood formation. It expresses itself in an extremely painful sensitivity to light, especially sunlight. The skin is usually nothing to look at. Not the UV radiation causes a burning of the skin, but the blue parts of the light. The liver can also be affected by the disease if too much Protoporphyrin deposits in the liver cells.
  Forum: By Share Code

odi01
Posted on: Feb 27 2018, 03:09 PM


Group: Member
Posts: 572

https://www.rarediseaseday.org/events/world
  Forum: By Share Code

odi01
Posted on: Feb 27 2018, 03:01 PM


Group: Member
Posts: 572

https://m.tio.ch/ticino/cronaca/1243602/il-...-prezzo-elevato

The drug could change your life, but it is war for the high price
The odyssey of a 35-year-old woman suffering from a serious illness potentially manageable with a medicine that the health insurance does not want to pay
 D. M.
LUGANO - It is a real odyssey that is experiencing A., 35-year-old resident in Ticino affected by a very rare pathology that requires a therapy from the costs to say the least prohibitive. At the origin of the problem there is precisely the assumption of expenses related to the administration of the "Scenesse" medicine, to be paid by the compulsory insurance, for the treatment of erythropoietic protoporphyria (a rare hereditary disease affecting 1 in 150,000 people in the population of Western Europe) of which the insured is affected. Costs that, in recent years, have skyrocketed so much as to push the health insurance to refuse to cover the difference by bringing the case up to the Federal Court.

TICINO
7/50
NO


145946
CANTONE26.02.18 - 16:01 | BED 15'556 UPDATE 19:36
The drug could change your life, but it is war for the high price
The odyssey of a 35-year-old woman suffering from a serious illness potentially manageable with a medicine that the health insurance does not want to pay
 D. M.
LUGANO - It is a real odyssey that is experiencing A., 35-year-old resident in Ticino affected by a very rare pathology that requires a therapy from the costs to say the least prohibitive. At the origin of the problem there is precisely the assumption of expenses related to the administration of the "Scenesse" medicine, to be paid by the compulsory insurance, for the treatment of erythropoietic protoporphyria (a rare hereditary disease affecting 1 in 150,000 people in the population of Western Europe) of which the insured is affected. Costs that, in recent years, have skyrocketed so much as to push the health insurance to refuse to cover the difference by bringing the case up to the Federal Court.

NO

First drug "offered", soon to 25 thousand francs per dose - The medicament, it must be said, despite appearing as the first effective therapy for this type of pathology, does not appear on the list of specialties nor has it been approved by the Swiss Institute for therapeutic agents (Swissmedic). The costs were initially assumed by the manufacturer in the context of a "compassionate use program" and then by sickness insurance for an amount of 6,560 francs per dose for 4 or 5 doses per year.

The surge in costs and the braking posed by Intras - Following the increase in the price of the medicine to 18,989 francs for 2016-2018 and 24,772 francs from 2019, the Intras health insurance recognized the reimbursement up to 6,560 francs per dose 4 times a year and, starting from November 2016, only 80% of this price.

On 21 September 2016, the Ticino Cantonal Insurance Court partially upheld A.'s appeal and ordered Intras to reimburse the insured for 4 doses of the medicine at a price of 18'989 francs each.

The appeals - Both Intras and A. (the latter did not consider it sufficient) have appealed to the Federal Court which partially upheld the appeals and referred the case to the Cantonal Court for a new decision.

Insufficient investigations - In short, the TF, after having recognized the therapeutic usefulness of the medicine to treat the pathology in question, considered that in the specific case the investigations carried out by the cantonal courts were insufficient to verify if the medicine was of real benefit for the insured and to establish how many annual Intras administrations were to be administered.

The Federal Court then referred the case to the Cantonal Court for a new appraisal. Too bad that, when asked several doctors and institutes specialized in the subject, no one has accepted to draw up the required expertise (who did it was rejected by one of the parties involved). The only doctor that the Cantonal Court was able to find was the attending physician of A. Based on the statements of the latter, Intras was ordered to reimburse 4 implants a year. For health insurance, however, the therapeutic usefulness of the medicine has not yet been ascertained. For the insured, however, the number of plants repaid would be insufficient. And here are the new appeals.

No turning point - The Federal Court found itself having to decide from a standstill. Noting that the Cantonal Court did not carry out the judicial review as requested (and was unable to establish the number of annual administrations if necessary), it then referred the case back to the lower authority for a new decision.
  Forum: By Share Code

odi01
Posted on: Feb 22 2018, 04:04 AM


Group: Member
Posts: 572

https://www.glassdoor.de/Bewertungen/Clinuv...en-E1446201.htm

https://www.glassdoor.de/Vorstellungsgespr%...ch-E1446201.htm


https://www.glassdoor.de/Vorstellungsgespr%...QTN_2331571.htm
  Forum: By Share Code

odi01
Posted on: Feb 20 2018, 02:31 PM


Group: Member
Posts: 572

https://globenewswire.com/news-release/2018...ositioning.html
  Forum: By Share Code

odi01
Posted on: Feb 10 2018, 03:02 AM


Group: Member
Posts: 572

Erythropoietic Protoporphyria: Carina's greatest enemy is the sun
A life-long struggle with a rare metabolic disease

For many people summer is the best season. But for Carina he is above all one thing: painful! She suffers from erythropoietic protoporphyria (EPP), a congenital metabolic disease that causes sunlight to cause severe pain on the skin. Later, the skin may redden and swell.

Barefoot runs Carina along the beach until she reaches the sea. She dives in, swims out with big trains, enjoys the cool water on her skin. And then she has to hurry up: Because the sun is rising - and by then she has to be in the hotel room again. Because when everyone else leaves for breakfast, Carina will read a book behind closed curtains or sleep a little longer. Only in the evening, after sunset, will she go out again.
Even a minute, even in winter ensures that I feel my skin hours later, "said the 36-year-old. "If I spend more time in the sun, I'm in pain for two or three days despite wearing protective clothing." These are sometimes so bad that Carina has to retire to her darkened bedroom. "I do not want to see anyone then, I'm completely exhausted physically, because the pain does not make me relax, let alone sleep."

It started in childhood
The first signs of the rare genetic defect showed in Carina already in the baby age: "I was nine months old, when my parents went with me on vacation to the Baltic Sea. As soon as I was outside, I only shouted. My parents could not figure out what was wrong with me - because the pain is already in EPP when there is nothing on the skin. "When she is two and a half, her parents visit a dermatologist with her. "She referred us to a university hospital - where we got the diagnosis EPP soon afterwards." Quick, as Carina knows today from other EPPs, who have been waiting for decades for the right diagnosis.

All treatment attempts are unsuccessful
Carina is treated with beta-carotene tablets. "It turned my skin orange, but the pain remained." But there is no other therapy for the little-explored disease at that time. So Carina swallows two to six tablets daily. She spends her childhood mainly in the house. When she's playing outside with other kids, she has to put up with the day-long fire on her skin. "At the age of 14, I had enough of tablet swallowing - and discontinued the medication." Since there are no alternatives, Carina researches in the next few years again on their own on the Internet, looking for other victims. "At the beginning of the 20s, I was finally connected to some. It was so good to talk about how other sufferers eased their pain, how they protected themselves from the sun and which doctors they had been to. Added to this was the feeling of not being alone anymore. "In order to further develop contact with other EPPers, Carina becomes a founding member of a self-help association.

I do not give up hope
For four months now, Carina has been trying out a new hormone implant - the only promising therapy on the market today. "Unfortunately, the drug has not helped me yet - my skin is slightly more pigmented, but the pain has remained the same. However, I know from other stakeholders that it did not work with them until after the second or third application, so I have not given up hope yet. A little relief in everyday life would be enough for me ... "

https://www.idee-fuer-mich.de/leben/aus-dem...sonne-4101.html

  Forum: By Share Code

odi01
Posted on: Feb 5 2018, 08:19 PM


Group: Member
Posts: 572

https://www.srf.ch/play/tv/puls/video/krank...d5-9d6519bebb29
  Forum: By Share Code

odi01
Posted on: Feb 5 2018, 07:19 PM


Group: Member
Posts: 572

https://www.srf.ch/play/tv/puls/video/wie-e...dc-f2e2699e3075
  Forum: By Share Code

odi01
Posted on: Jan 30 2018, 08:12 PM


Group: Member
Posts: 572

After Clinuvel's investor relations work has remained at a very low level in recent years, I am delighted that Peter Thilo Hasler, the founder of Research House Sphene Capital (among other things, is the author of stocks: Theoretical fundamentals explained in practice) who has taken up coverage for Clinuvel Pharmaceuticals. In his first extensive analysis, he determined a price target of 31.70 AUD / share (20.67 EUR / share).


Sphene Capital is an independent research house with a focus on smaller companies with a focus on German-speaking countries.

With his initial analysis of Clinuvel Pharmaceuticals, Hasler provides an impressive and comprehensive summary of the current state of knowledge on Clinuvel, the progress in the business, but also numerous contextual information on the diseases addressed, and a detailed financial projection until the year 2032.

While he clearly points out in the text the extended business potential beyond EPP and describes the key drivers, his valuation model is based solely on EPP - he considers EPP revenues and cash flows to be in a phase of market saturation and goes for The steady state (terminal value) of continued high, stable cash flows from EPP, without considering the re-investment of cash flows generated in new fields of application, which would have certainly given the valuation of the current high return on equity valuation. Despite this conservative approach, it achieves a price target of EUR 20.67 per share, which corresponds to a growth potential of 259% (vs. closing price on 29.01.2018 - EUR 5.75). By purely considering EPP without vitiligo, the price target is at the lower end of the range of 20-24 EUR that I have determined.

The essential similarities and differences to my previous evaluation are the following:

Similar sales projection until 2019, then slightly more aggressive than my model (assuming continued Scenesse roll-outs across Europe and US)
no consideration / quantification of vitiligo sales
more realistic consideration of taxes (flat-rate with me, tax allowances from previous losses are taken into account here)
Comparable assumptions on weighted average cost of capital (WACC) in the initial phase, much more optimistic in the later stage (which is realistic in my view, as the risk premium for a well-established company is likely to decline significantly and the high assumed cash cushion reduces the risk)



http://minussinus.de/2018/01/30/erster-una...ursziel-20-eur/
  Forum: By Share Code

odi01
Posted on: Jan 30 2018, 07:38 PM


Group: Member
Posts: 572

Anlass der Studie: Initiation of Coverage Empfehlung: Buy seit: 30.01.2018 Kursziel: AUD 31,70 Kursziel auf Sicht von: 12 Monate Letzte Ratingänderung: - Analyst: Peter Hasler The light protection enabler We're initiating coverage of Australian Clinuvel with a buy rating and a price target of AUD 31.70 per share, since we believe investors are not fully factoring in potential opportunities to Clinuvel's long-term growth in the global skin protection market. The orphan disease drug company is dramatically expanding top-line growth in the near-term as we expect the company to expand its global footprint in EPP. Apart from these significant growth opportunities, that even a rare disease like EPP offers, we expect even more in the years to come, since (1) Clinuvel is expected to launch its vitiligo product in 2021e, representing a substantial larger market than the rare disease EPP, (2) the launch of a topical product should make room for the mass market of non-prescription skin care solutions, and (3) Clinuvel could also offer a treatment for various Central Nervous System disorders among them MS, dementia, Alzheimer's, Parkinson's, ALS, or Huntington's. Apart from EPP, none of these growth opportunities have so far been factored in into our company valuation, leaving substantial upside to our price target in the long-term. Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/16065.pdf

Original-Research: Clinuvel Pharmaceuticals Ltd (von Sphene Capital GmbH): Buy | wallstreet-online.de - Vollständiger Artikel unter:
https://www.wallstreet-online.de/nachricht/...apital-gmbh-buy
  Forum: By Share Code

odi01
Posted on: Jan 28 2018, 05:04 PM


Group: Member
Posts: 572

Help in the form of an implant
Dr. Esther Wißmüller, a dermatologist from Munich, confirms that there is a medication in the form of an artificially produced endogenous hormone that is transplanted under the skin in the form of a rod. "The drug stimulates tanning of the skin to protect it."

Markus Dürr also receives this medicine. However, it only lasts eight weeks.
Markus Dürr:"The drug is only available in very few places in Germany. Only advertised institutes for EPP may administer it." In order to preserve the implant, Markus Dürr takes the long way to Zurich, because the nearest institute for EPP in Germany is in Düsseldorf. The assumption of costs for the drug is also problematic. For this reason, Markus Dürr has fought with other patients for approval of the drug at several demonstrations in the past, including in London at the European Medicines Agency and in Berlin. It's not about going on holiday, it's about leading a normal life.

http://grundkurs-online.de/lichtkrankheit-epp/

  Forum: By Share Code

odi01
Posted on: Dec 19 2017, 04:39 PM


Group: Member
Posts: 572

https://youtu.be/bJ8U3qr8uZM
  Forum: By Share Code

odi01
Posted on: Dec 15 2017, 04:55 PM


Group: Member
Posts: 572

Twelve-year-old Oliver is a shadow jumper. So called sufferers of the rare disease erythropoietic protoporphyria, in short EPP. Shadow jumpers suffer from a genetic defect that leads to painful photosensitivity. On Thursday, November 16, 2017, Oliver reported on the first Regensburg Charity Dinner of the ZSER e.V. to the approximately 80 invited guests in the Ducal Hall from his long ordeal to diagnosis and therapy at the Center for Rare Diseases Regensburg (ZSER). Oliver's story illustrated the challenge of treating rare diseases: there are only a handful of victims of more than 8,000 rare diseases, who can not rely on a nationwide supply network. The purpose of the charity dinner was therefore to promote the work of the Center for Rare Diseases Regensburg in health care and research and to promote it further. Prominent guests of honor of the evening were Eva Luise Köhler, Chairwoman of the Eva Luise and Horst Köhler Foundation for People with Rare Diseases, ski racer Rosi Mittermaier and Christian Neureuther as well as the ZSER patron, actor and director Marcus Mittermeier. Radio and TV presenter Markus Othmer led the evening.

https://www.regensburger-nachrichten.de/new...hl-der-seltenen
  Forum: By Share Code

odi01
Posted on: Dec 15 2017, 04:44 AM


Group: Member
Posts: 572

http://www.actasanitaria.com/ipt-abordados...terapeutico-26/
  Forum: By Share Code

odi01
Posted on: Dec 14 2017, 03:08 AM


Group: Member
Posts: 572

https://bazonline.ch/leben/gesellschaft/Die.../story/17458605

In Australia, the drug Scenesse has been manufactured for several years. The active substance is a synthetic variant of a hormone called alpha-MSH, which stimulates the skin tanning in the body. Falchetto is taking this implant, which has to be renewed every two months, for several years. "When I first got the medication and then had to go to the sun, I was very scared," he recalls. After an exhausting ten minutes, he noticed that his skin changed nothing. After thirty minutes, there would still have been no symptoms. "Then I was completely overwhelmed by the fact that the active ingredient actually works." Shortly thereafter, he was in the swimming pool for the first time in his life and then dried in the sun for 15 minutes. "I never thought that someday, for me, sun would not only mean pain, but would be warming and soothing. It was like a release from the prison of the disease. "

The drug does not cure EPP people, but acts as a therapy. The European Medicines Agency approved Scenesse 2014 for the treatment of adult EPP patients, but this is not yet the case in Switzerland. That means according to Falchetto a constant fight with the health insurance companies. "I hope so," says Anouschka Zorzetti, "that this fight will soon end and Enya will be able to benefit from the therapy when she is 18." After a moment, she adds, "Maybe then she can finally lead an almost normal life. »
  Forum: By Share Code

odi01
Posted on: Nov 30 2017, 03:25 AM


Group: Member
Posts: 572

http://blogs.sciencemag.org/pipeline/archi...izards-any-more
  Forum: By Share Code

3 Pages (Click to Jump) V   1 2 3 >

Cant find what you are looking for? Show all active topics from the last 3 months


New Posts  New Replies
No New Posts  No New Replies
Hot topic  Hot Topic (New)
No new  Hot Topic (No New)



TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING